Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD20 antibody with chidamide, prednisone, etoposide, and lenalidomide induction followed by CD20 antibody + bendamustine consolidation in refractory DLBCL
ChiCTR2100046855Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, tucidinostat, prednisone, etoposide, lenalidomide and 1 more in diffuse large B-cell lymphoma (DLBCL), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Objective response rate. Started Jul 2021; status: recruiting.
02
Drugs
rituximabtucidinostatprednisoneetoposidelenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2100046855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046855.